$59.98
0.00%
Nasdaq, Mon, Dec 23 2024
ISIN
US54300N1037
Symbol
LBPH

Longboard Pharmaceuticals Inc Stock price

$59.98
+0.07 0.12% 1M
+39.16 188.09% 6M
+53.95 894.69% YTD
+53.98 899.67% 1Y
+54.58 1,010.74% 3Y
+43.98 274.88% 5Y
+43.98 274.88% 10Y
Nasdaq, Closing price Mon, Dec 23 2024
+0.00 0.00%
ISIN
US54300N1037
Symbol
LBPH
Sector
Industry

Key metrics

Market capitalization $2.34b
Enterprise Value $2.06b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.51
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-87.45m
Free Cash Flow (TTM) Free Cash Flow $-65.93m
Cash position $288.45m
EPS (TTM) EPS $-2.24
Short interest 6.53%
Show more

Is Longboard Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Longboard Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Longboard Pharmaceuticals Inc forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Longboard Pharmaceuticals Inc forecast:

Buy
50%
Hold
50%

Financial data from Longboard Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
0% 0%
-
-0.01 -0.01
0% 0%
-
- Selling and Administrative Expenses 20 20
66% 66%
-
- Research and Development Expense 67 67
65% 65%
-
-87 -87
65% 65%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -87 -87
65% 65%
-
Net Profit -76 -76
50% 50%
-

In millions USD.

Don't miss a Thing! We will send you all news about Longboard Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Longboard Pharmaceuticals Inc Stock News

Neutral
Business Wire
about 2 months ago
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported third quarter 2024 financial results. RECENT UPDATES: In October, announced an agreement for H. Lundbeck A/S (Lundbeck) to ...
Neutral
Business Wire
about 2 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Longboard Pharmaceuticals, Inc. (NasdaqGM: LBPH) to H. Lundbeck A/S. Under the terms of the proposed transaction, shareholders of Longboard will receive $60.00 in cash for each share of Longboard that they own. KS...
Neutral
GlobeNewsWire
2 months ago
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
More Longboard Pharmaceuticals Inc News

Company Profile

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Lind
Employees 50
Founded 2020
Website www.longboardpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today